Skip to main content

Table 3 Baseline clinical and biological characteristics of matched patients

From: Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation

Characteristics

CD56 positive

CD56 negative

ASCT

non-ASCT

ASCT

non-ASCT

n = 93

n = 93

n = 40

n = 40

n (%)

n (%)

n (%)

n (%)

Median age (range) [years]

56 (36–65)

57 (38–65)

57 (38–65)

57 (35–65)

ISS stage

 I

16 (17.2)

13 (14.0)

11 (27.5)

9 (22.5)

 II

34 (36.6)

39 (41.9)

12 (30.0)

12 (30.0)

 III

43 (46.2)

41 (44.1)

17 (42.5)

19 (47.5)

Hemoglobin

  < 100 g/L

57 (61.3)

62 (66.7)

20 (50.0)

24 (60.0)

  ≥ 100 g/L

36 (38.7)

31 (33.3)

20 (50.0)

16 (40.0)

Serum creatinine

  ≤ 2 mg/dL

80 (86.0)

80 (86.0)

35 (87.5)

36 (90.0)

  > 2 mg/dL

13 (14.0)

13 (14.0)

5 (12.5)

4 (10.0)

Corrected serum calcium

  ≤ 2.75 mmol/L

82 (88.2)

80 (86.0)

37 (92.5)

36 (90.0)

  > 2.75 mmol/L

11 (11.8)

13 (14.0)

3 (7.5)

4 (10.0)

Lactate dehydrogenase

  ≤ 250 U/L

83 (89.2)

81 (87.1)

34 (85.0)

33 (82.5)

  > 250 U/L

10 (10.8)

12 (12.9)

6 (15.0)

7 (17.5)

Cytogenetic abnormalities by FISH

del(17p13)

 abnormality

10 (10.8)

12 (12.9)

2 (5.0)

1 (2.5)

 non-abnormality

83 (89.2)

81 (87.1)

38 (95.0)

39 (97.5)

t(14; 16)

 abnormality

0 (0.0)

0 (0.0)

3 (7.5)

5 (12.5)

 non-abnormality

93 (100.0)

93 (100.0)

37 (92.5)

35 (87.5)

t(4; 14)

 abnormality

26 (28.0)

25 (26.9)

0 (0.0)

0 (0.0)

 non-abnormality

67 (72.0)

68 (73.1)

40 (100.0)

40 (100.0)